Golimumab, a novel human anti-TNFα IgG1κ mAb, is safe for the treatment of psoriatic arthritis (PsA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) (Mazumdar and Greenwald, 2009; Kay and Rahman, 2010; Shealy et al., 2010; Melo et al., 2021). This evidence concerns the gene TNF and rheumatoid arthritis.